Make the Most of Azure DevOps in Healthcare

Current diagnostic methods for lower respiratory specimens typically take one to two days to identify most bacterial pathogens. During that time, clinicians must rely on guideline recommendations and clinical diagnosis to guide empiric therapy, which is not optimized based on the patient’s individual pathogen. The BioFire Pneumonia Panel will provide pathogen identification in a much shorter timeframe and may allow clinicians to optimize targeted pathogen-specific therapy sooner. The BioFire Pneumonia Panel is a rapid multiplex-PCR test that identifies 33 targets, including 18 bacteria, 8 viruses and 7 antimicrobial resistance genes from lower respiratory tract specimens in about an hour. It provides semi-quantitative results (in copies/ml) for 15 of the bacterial targets. This new feature provided by multiplex-PCR testing may help clinicians and laboratorians separate colonizing from pathogenic levels of bacteria.

The impact of Brexit on the life sciences industry: separating fact from fiction to prepare for the impact of a change in the relationship between the UK and EU.

Advanced therapy medicinal products (ATMPs) comprise a category of innovative and complex biological products and hold one of the keys to personalised treatment. It holds promises as treatments for untreatable and high burden diseases.

Pharmaceutical manufacturers often have the task of reducing waste to meet company expectations, document the process to meet regulatory requirements and improve quality to meet customer specifications. Let's be honest, not achieving any of the above points is not an option in most pharmaceutical companies. That's where the capacity analysis comes into play.